Coronavírus Página 1

ECDC - Rapid risk assessment: Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 15th update

European Centre for Disease Prevention and ControlAlthough SARS-CoV-2 transmission remains widespread in large parts of the EU/EEA, most countries report declining trends in 14-day COVID-19 notification rates, hospital and intensive care unit...

ECDC - Countering online vaccine misinformation in the EU/EEA

European Centre for Disease Prevention and ControlVaccines authorised by the European Medicines Agency for use in the European Union (EU) are known to be safe and effective in preventing infectious diseases. Nonetheless, misinformation that...

JAMA - SARS-CoV-2–Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women

JAMA NETWORKOn December 20, 2020, Israel initiated a national vaccination program against COVID-19. One prioritized group was health care workers, many of whom are breastfeeding women. Despite the fact that the vaccine trial did not include...

NEJM - Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

The New England Journal of MedicineThe B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has...

BMJ - Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children

British Medical JournalAs the majority of adults in multiple rich western countries have now received at least one dose of a covid-19 vaccine, the focus is turning to children. While there is wide recognition that children’s risk of severe...

NEJM - Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

The New England Journal of MedicineInformation is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome...

NEJM - Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

The New England Journal of MedicinePatients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment...

ECDC - Threat Assessment Brief: Implications for the EU/EEA on the spread of the SARS-CoV-2 Delta (B.1.617.2) variant of concern

European Centre for Disease Prevention and ControlBased on the available evidence, the SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) is 40-60% more transmissible than the Alpha (Β.1.1.7) VOC and may be associated with higher risk of...

ECDC - Indicator framework to evaluate the public health effectiveness of digital proximity tracing solutions

European Centre for Disease Prevention and Control

As they respond to the COVID-19 pandemic, countries worldwide have increasingly looked to digital technologies in support of public health measures for contact tracing.

CDC - Interim Guidance for Antigen Testing for SARS-CoV-2

Centers for Disease Control and PreventionThis interim guidance is intended for healthcare providers who order antigen tests, receive antigen test results, or perform point-of-care testing, as well as for laboratory professionals who...

BMJ - How long does covid-19 immunity last?

British Medical JournalHow long does covid-19 immunity last? This is difficult to say definitively. When the body’s immune system responds to an infection, it isn’t always clear how long any immunity that develops will persist. Covid-19 is a very...

DGS - Campanha de Vacinação contra a COVID-19 Vacina COMIRNATY®

Norma da Direção-Geral da Saúde

DGS - Campanha de Vacinação contra a COVID-19 Vacina SPIKEVAX® (anteriormente designada COVID-19 Vaccine Moderna®